Capmatinib (INC280) in MET Delta EX14-Mutated Advanced NSCLC: Efficacy Data from the Phase 2 Geometry MONO-1 Study

R. S. Heist; J. Wolf; T. Seto; J. -Y. Han; N. Reguart; H. J. M. Groen; D. S. W. Tan; T. Hida; M. D. Jonge; S. V. Orlov; E. F. Smit; P. -J. Souquet; J. Vansteenkiste; M. Giovannini; S. L. Mouhaer; A. Robeva; M. Waldron-Lynch; E. B. Garon

Capmatinib (INC280) in MET Delta EX14-Mutated Advanced NSCLC: Efficacy Data from the Phase 2 Geometry MONO-1 Study

R. S. Heist, J. Wolf, T. Seto, J. -Y. Han, N. Reguart, H. J. M. Groen, D. S. W. Tan, T. Hida, M. D. Jonge, S. V. Orlov, E. F. Smit, P. -J. Souquet, J. Vansteenkiste, M. Giovannini, S. L. Mouhaer, A. Robeva, M. Waldron-Lynch, E. B. Garon

Onderzoeksoutput › Academic

Originele taal-2	English
Pagina's (van-tot)	S1126
Aantal pagina's	1
Tijdschrift	Journal of Thoracic Oncology
Volume	14
Nummer van het tijdschrift	11
Status	Published - nov.-2019

Handle.net

Permanente koppeling

Citeer dit

Heist, R. S., Wolf, J., Seto, T., Han, J. -Y., Reguart, N., Groen, H. J. M., Tan, D. S. W., Hida, T., Jonge, M. D., Orlov, S. V., Smit, E. F., Souquet, P. -J., Vansteenkiste, J., Giovannini, M., Mouhaer, S. L., Robeva, A., Waldron-Lynch, M., & Garon, E. B. (2019). Capmatinib (INC280) in MET Delta EX14-Mutated Advanced NSCLC: Efficacy Data from the Phase 2 Geometry MONO-1 Study. Journal of Thoracic Oncology, 14(11), S1126.

@article{2e98507785144d7991894fc6631c97a9,

title = "Capmatinib (INC280) in MET Delta EX14-Mutated Advanced NSCLC: Efficacy Data from the Phase 2 Geometry MONO-1 Study",

keywords = "NSCLC, MET, INC280, Capmatinib",

author = "Heist, {R. S.} and J. Wolf and T. Seto and Han, {J. -Y.} and N. Reguart and Groen, {H. J. M.} and Tan, {D. S. W.} and T. Hida and Jonge, {M. D.} and Orlov, {S. V.} and Smit, {E. F.} and Souquet, {P. -J.} and J. Vansteenkiste and M. Giovannini and Mouhaer, {S. L.} and A. Robeva and M. Waldron-Lynch and Garon, {E. B.}",

year = "2019",

month = nov,

language = "English",

volume = "14",

pages = "S1126",

journal = "Journal of Thoracic Oncology",

issn = "1556-0864",

publisher = "ELSEVIER SCIENCE INC",

number = "11",

}

Heist, RS, Wolf, J, Seto, T, Han, J-Y, Reguart, N, Groen, HJM, Tan, DSW, Hida, T, Jonge, MD, Orlov, SV, Smit, EF, Souquet, P-J, Vansteenkiste, J, Giovannini, M, Mouhaer, SL, Robeva, A, Waldron-Lynch, M & Garon, EB 2019, 'Capmatinib (INC280) in MET Delta EX14-Mutated Advanced NSCLC: Efficacy Data from the Phase 2 Geometry MONO-1 Study', Journal of Thoracic Oncology, vol. 14, nr. 11, blz. S1126.

TY - JOUR

T1 - Capmatinib (INC280) in MET Delta EX14-Mutated Advanced NSCLC

T2 - Efficacy Data from the Phase 2 Geometry MONO-1 Study

AU - Heist, R. S.

AU - Wolf, J.

AU - Seto, T.

AU - Han, J. -Y.

AU - Reguart, N.

AU - Groen, H. J. M.

AU - Tan, D. S. W.

AU - Hida, T.

AU - Jonge, M. D.

AU - Orlov, S. V.

AU - Smit, E. F.

AU - Souquet, P. -J.

AU - Vansteenkiste, J.

AU - Giovannini, M.

AU - Mouhaer, S. L.

AU - Robeva, A.

AU - Waldron-Lynch, M.

AU - Garon, E. B.

PY - 2019/11

Y1 - 2019/11

KW - NSCLC

KW - MET

KW - INC280

KW - Capmatinib

M3 - Meeting Abstract

VL - 14

SP - S1126

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 11

ER -